MED

Zacks highlights three stocks with Rank #1 buy ratings and strong momentum: Nucor Corporation (steel manufacturing) with 8.6% three-month gains and 6.5% earnings estimate increase; Cinemark Holdings (cinema exhibition) with 29.5% three-month gains and 7.3% earnings estimate increase; and Medifast Inc (weight management) with 10.0% three-month gains and 47.2% earnings estimate increase.

Medifast (MED) reported Q2 2026 revenues of $76.4 million, down 27.6% year-over-year due to a 48.7% decline in active earning coaches to 11,700. However, the company showed positive signs with revenue per active coach increasing 41% to $6,529 for a third consecutive quarter, improved client retention, and strong referral program performance. Management expects Q3 revenues of $60-$80 million with continued coach productivity improvements.

Trilivy, a metabolic health system by Medifast, identifies five key factors that drive weight regain: slowed metabolism, hormonal changes, lack of human support, set point theory, and metabolic adaptation. The company's Metabolic Synchronization® framework addresses these through lean mass preservation and visceral fat reduction, with clinical data showing 98% lean mass retention and 14% visceral fat reduction at 16 weeks.